---
title: "Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291454858.md"
description: "Maxim Group analyst Jason McCarthy reiterated a Buy rating on MediciNova with an unchanged $6 price target. The decision is driven by the company's advancing pipeline, including upcoming data from the MN-001 Phase 2 trial for hypertriglyceridemia and NAFLD. Additionally, the MN-166 ALS program's pivotal COMBAT-ALS trial is expected to report results by late 2026, potentially leading to an NDA submission in early 2027. McCarthy views the risk/reward profile as attractive based on these catalysts."
datetime: "2026-07-01T19:35:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291454858.md)
  - [en](https://longbridge.com/en/news/291454858.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291454858.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Medicinova, retaining the price target of $6.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Jason McCarthy has given his Buy rating due to a combination of factors, including MediciNova’s advancing pipeline and approaching catalysts. He points to the completed Phase 2 trial of MN-001 in patients with hypertriglyceridemia, NAFLD, and type 2 diabetes, where upcoming data on liver fat and triglyceride reduction could validate its multi-pathway mechanism and prior signals of lipid improvement.

McCarthy also emphasizes the MN-166 ALS program, with the pivotal COMBAT-ALS Phase 2b/3 trial expected to deliver topline results by year-end 2026, potentially enabling an NDA submission in the first half of 2027. With additional real-world evidence coming from the SEANOBI expanded-access study and supportive prior safety and efficacy data, he views the overall risk/reward as attractive, maintaining his Buy rating and a $6 price target, which remains unchanged.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [MediciNova CEO Iwaki base salary rises to $690,246 under new employment agreement](https://longbridge.com/en/news/296348115.md)
- [Analyst Reiterates Buy on ProMIS Neurosciences, Maintaining $35 Price Target Amid Strong Cash Position and PMN310 Clinical Progress](https://longbridge.com/en/news/296004030.md)
- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Cantor Fitzgerald Sticks to Its Buy Rating for DeFi Development Corporation (DFDV)](https://longbridge.com/en/news/296108554.md)
- [This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday](https://longbridge.com/en/news/296102902.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**